Posted On: 03/08/2014 7:00:44 PM
Post# of 7769
Scrips is just a few weeks from closing out Q1 2014, the year the company anticipates to be its breakout year. On May 17, 2013, the company reported $287,374 in total revenues, which was the highest total quarterly revenues reported in the first 9 months of 2013 ($91,628 Q2, $73,267 Q3, ? Q4).
Assuming the Compounding Pharmacy (CP) revenues of $57K after the first 3 to 4 days of the CP agreement, Scrips' March 2014 CP revenues may hit between $309K and $412K.
Considering WholesaleRx put up $268K in January revnues, I will assume they did at least $300K in February and $350K in March, for a Q1 total about about $918K. I have no idea how much of this would actually flow to SCRC, but I will conservatively assume about $125K.
Per the Q3 10K for 2013, the company reported about $57K from the contract packager (which I believe to be the DOD revenues).
And since Scrips reported its first PIMD order in its 10/31/13 PR, I assume the company is receiving some amount of revenues from PIMD as that revenue stream ramps up. This is clearly the mystery revenue source and, so, I will assume no PIMD revenues for now.
We also have the potential to receive an order from RapiMeds Hong Kong between now and 3/31, but I am not holding my breath.
To that end, excluding the potential revenues from PIMD and RapiMeds HK, my conservative Q1 revenue range is between $491K to $594K. If so, revenues would be between 71% and 107% higher than the Q1 FY13 revenues -- not too shabby. Moreover, and order from HK and PIMD revenues may surprise us all and actually double my estimated revenues range.
For the first 9 months of 2013, SCRC's total reported revenues were $452,268. So if my revenue estimates are accurate, Scrips reported revenues for Q1 2014 will exceed the first 9 months of 2013 revenues. This will be significant.
I am looking forward to reading the actual numbers in a couple months.
Enjoy the remainder of the weekend.
BSAV
Assuming the Compounding Pharmacy (CP) revenues of $57K after the first 3 to 4 days of the CP agreement, Scrips' March 2014 CP revenues may hit between $309K and $412K.
Considering WholesaleRx put up $268K in January revnues, I will assume they did at least $300K in February and $350K in March, for a Q1 total about about $918K. I have no idea how much of this would actually flow to SCRC, but I will conservatively assume about $125K.
Per the Q3 10K for 2013, the company reported about $57K from the contract packager (which I believe to be the DOD revenues).
And since Scrips reported its first PIMD order in its 10/31/13 PR, I assume the company is receiving some amount of revenues from PIMD as that revenue stream ramps up. This is clearly the mystery revenue source and, so, I will assume no PIMD revenues for now.
We also have the potential to receive an order from RapiMeds Hong Kong between now and 3/31, but I am not holding my breath.
To that end, excluding the potential revenues from PIMD and RapiMeds HK, my conservative Q1 revenue range is between $491K to $594K. If so, revenues would be between 71% and 107% higher than the Q1 FY13 revenues -- not too shabby. Moreover, and order from HK and PIMD revenues may surprise us all and actually double my estimated revenues range.
For the first 9 months of 2013, SCRC's total reported revenues were $452,268. So if my revenue estimates are accurate, Scrips reported revenues for Q1 2014 will exceed the first 9 months of 2013 revenues. This will be significant.
I am looking forward to reading the actual numbers in a couple months.
Enjoy the remainder of the weekend.
BSAV
(0)
(0)
